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Abstract
Background: The use of stem cells, including mesenchymal stem cells (MSCs), for regenerative medicine is gaining
interest for the clinical benefits so far obtained in patients. This study investigates the use of adipose autologous
tissue in combination with platelet-rich plasma (PRP) to improve the clinical outcome of patients affected by systemic
sclerosis (SSc).
Methods: Adipose-derived mesenchymal stem cells (AD-MSCs) and PRPs were purified from healthy donors and SSc
patients. The multilineage differentiation potential of AD-MSCs and their genotypic–phenotypic features were
investigated. A cytokine production profile was evaluated on AD-MSCs and PRPs from both healthy subjects
and SSc patients. The adipose tissue-derived cell fraction, the so-called stromal vascular fraction (SVF), was coinjected
with PRP in the perioral area of SSc patients.
Results: Histopathological and phenotypical analysis of adipose tissue from SSc patients revealed a disorganization of
its distinct architecture coupled with an altered cell composition. Although AD-MSCs derived from SSc patients
showed high multipotency, they failed to sustain a terminally differentiated progeny. Furthermore, SVFs derived from
SSc patients differed from healthy donors in their MSC-like traits coupled with an aberrant cytokine production profile.
Finally, the administration of PRP in combination with autologous SVF improved buccal’s rhyme, skin elasticity and
vascularization for all of the SSc patients enrolled in this study.
Conclusions: This innovative regenerative therapy could be exploited for the treatment of chronic connective tissue
diseases, including SSc.
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Background
Regenerative medicine has been the subject of numerous
studies, and to date several successes have been reported
in regenerating nonfunctional tissue or damaged organs
affected by traumas and congenital and/or acquired dis-
orders [1, 2]. Tissue engineering often resorts to the use
of stem cells and/or synthetic scaffold as supporting
structures [3, 4].
Mesenchymal stem cells (MSCs), thanks to their
multilineage differentiation potential, are the most
promising candidates for regenerative medicine tech-
niques [5, 6]. Recent findings have shown that adipose
tissue is an important source of MSCs [7]. Therefore,
this prompted great interest in the scientific community,
leading to the discovery of advanced techniques used for
the collection and isolation of MSCs from lipoaspirates
[8, 9], and their use in the clinic. Lipofilling is a surgical
protocol that was standardized by Dr Sidney Coleman in
1997 [10], aiming at the transfer of autologous adipose
tissue. The current lipofilling technique consists of three
phases: subcutaneous tumescent liposuction from the
abdomen, medial knee, or trochanter regions; centrifuga-
tion of the lipoaspirate sample to remove blood elements
and the oil fraction from adipose components; and au-
tologous injection of “purified” adipose tissue [11, 12].
Adipose tissue is composed of mature adipocytes,
fibroblasts, adipose-derived mesenchymal stem cells
(AD-MSCs), immune system cells, and endothelial cells,
which are grouped as the stromal vascular fraction
(SVF) [13]. The presence of all these cellular elements,
in particular the large number of AD-MSCs, makes the
SVF the most prominent candidate for lipofilling thera-
peutic success [8, 14–16].
In fact, AD-MSCs secrete high levels of growth factors
and cytokines such as vascular endothelial growth factor
(VEGF) and hepatocyte growth factor (HGF), which are
all crucial molecules for lipotransfer engraftment and
tissue regeneration [3–5, 17].
AD-MSCs are endowed with great multilineage differ-
entiation potential and relevant regenerative properties
[18–20]. AD-MSCs are able to grow in suspension as
spheroids without serum and they can be identified
through a high expression level of the CD271
marker [21, 22].
Systemic sclerosis (SSc) is a chronic connective tissue
disease associated with autoimmune pathogenesis and
unknown etiology [23, 24]. It causes a widespread micro-
angiopathic vascular dysfunction and morphofunctional
alterations [25].
The most affected districts in SSc patients are the
joints of distal limbs and perioral and malar areas. A
gradual reduction was observed in the opening and ex-
tension rates of the labialis rhyme, due to fibrosis and
loss of endothelium integrity, inflammatory mononuclear
infiltrate, and high production of reactive oxygen species
(ROS) [25–27].
These conditions promote a compensatory VEGF over-
production by the endothelium. In healthy subjects the in-
crease of VEGF is coupled with platelet-derived growth
factor (PDGF), endothelin-1 (ET-1), transforming growth
factor beta (TGF-β), connective tissue growth factor
(CTGF), and monocyte chemoattractant protein-1 (MCP-
1) production, thus promoting angiogenesis. SSc patients
show a high production of VEGF, which is not however
followed by an improvement of endothelial capillarity, giv-
ing rise to telangiectasia [28, 29]. Being that a single lipo-
filling treatment usually is not sufficient in order to obtain
efficient regeneration in SSc patients, a combination of au-
tologous tissue together with an abundant cytokine source
would be preferable [30–33].
Platelet-rich plasma (PRP) consists of a gel fraction ob-
tained from peripheral blood. PRP contains a high num-
ber of platelets, cytokines, and growth factors. Different
studies have shown that PRP promotes coagulation and
wound healing, exerting an antiphlogistic effect on the
acceptor site and hence stimulating rapid tissue regener-
ation [34, 35]. Several studies have demonstrated that
PRP has a beneficial impact on the regenerative potential
of MSCs, and that the combined use of PRPs and lipoas-
pirates increases graft survival while maintaining the
plumping effect in breast reconstruction [36, 37].
However, no study has yet investigated the synergistic
effect of lipoaspirate and PRP injections on SSc patients.
There has been no in-depth study performed into their
effect at a molecular level, in particular with regard to
the differences between SVFs and PRPs in healthy indi-
viduals as opposed to SSc patients.
Our study is the first to assess the positive effects of the
combined use of autologous lipoaspirate and PRP, in treat-
ment of typical perioral and malar alterations in SSc pa-
tients. Here we compare the multilineage differentiation
potential of AD-MSCs from healthy subjects and SSc pa-
tients. Moreover, we characterized PRPs and SVFs derived
from healthy subjects as well as SSc patients in order to
predict their possible contribution in tissue regeneration.
Finally, we tested the positive effect of combined SVF–
PRP treatment on SSc patients. SSc patients were moni-
tored for 3 months with periodical evaluations. All
clinical outcome evaluations have highlighted a wide-
spread and progressive improvement in morphological
and functional malar and perioral alterations. Our re-
sults suggest that this combined treatment could be con-
sidered promising for SSc patients.
Methods
Patient selection
Patients were treated in compliance with our depart-
ment’s policy, following patient’s written consent on
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adipose tissue harvest and its use for research purposes.
The study was approved by the ethics committee
Palermo-1 Polyclinic Paolo Giaccone of Palermo with re-
port N°1/2016.
A group of six SSc patients affected by cutaneous sys-
temic sclerosis (dcSSc) were selected. These subjects are
between the ages of 41 and 63 without malignancies, not
pregnant, not lactating or making use of immune modu-
lator drugs, and not having undergone antiplatelet and/
or vasodilator treatments in the last 20 days (Table 1).
For our healthy control group, we selected five lipoas-
pirate samples from 50 of our healthy subjects (16
males, 34 females) [20] (Table 1). The selection of
healthy samples was based on their capability to give
rise to AD-MSCs.
Adipose tissue and culture
The withdrawal of adipose tissue was performed under
conscious sedation through local infiltration of 150 cm3
of Klein solution. A 10-gauge cannula connected to a
10-ml syringe with luer-lock-type attack was used for
the liposuction. Then 90–140 cm3 of subcutaneous
adipose tissue was extracted from each patient.
Lipoaspirates from healthy subjects were obtained
using a liposuction procedure. These subjects had
been previously screened to ensure the absence of
chronic illness. The sample was centrifuged for
5 min at 2700 rpm. After centrifugation, the samples
were stratified into three layers, the upper layer
representing the oily component, the middle one con-
sisting of a solid tissue layer, and the bottom layer
composed of MSCs and blood elements. Lipoaspirate
samples deprived of the blood and oily phases were
divided into two fractions: 12–40 cm3 were used for
in-vitro analyses and 22–50 cm3 for the surgical
procedure.
Lipoaspirates from SSc patients and healthy donors
were digested for 30 min at 37 °C, in the presence of col-
lagenase (1.5 mg/ml; GIBCO) and hyaluronidase
(20 mg/ml; Sigma). The digested samples were centri-
fuged and washed with PBS. The obtained pellet was
suspended in serum-free stem cell-specific medium, sup-
plemented with bFGF (10 ng/ml; Sigma) and EGF
(20 ng/ml; Sigma), in ultra-low adhesion culture flasks
(Corning) as described previously [38]. In these condi-
tions, cells grew as floating spheroids, called AD-MSCs
[20]. StemPro™ Human Adipose-Derived Stem Cells
(ADSCs; ThermoFisher), cultured as the manufacturer
recommended, were used as the MSC control.
Flow cytometry
AD-MSCs and freshly purified samples were harvested,
washed twice in PBS, and then stained with conjugated
antibodies against CD271-ALEXA FLUOR 647 (C40-
1457, IgG1k; BD), CD44-FITC (G44-26, IgG2bk; BD),
CD90-PE (5E10, IgG1k; BD), and CD45-FITC (5B1,
IgG2a; Miltenyi), or with purified primary antibodies
against CD29 (MAR4, IgG1k; BD), CD9 (M-L13, IgG1k;
BD), and CD73 (AD2, IgG1k; BD). Where necessary,
cells were then labeled with goat anti-mouse IgG-Alexa
Fluor 488 secondary antibody (Invitrogen). Correspond-
ing isotype-matched antibodies, CD3-Alexa Fluor 647
(UCHT1, IgG1k; BD), CD3-FITC (UCHT1, IgG1k; BD),
CD3-PE (UCHT1, IgG1k; BD), CD8 (BW135/80, IgG2a;
Miltenyi), and Purified CD3 (UCHT1, IgG1k; BD), were
used as negative controls. Samples were acquired using
an AccuriC6 (BD) flow cytometer. All data were ana-
lyzed by FlowJo software (Tree-Star).
Table 1 Case description
Case Gender Liposuction area Age/disease
durationa (years)
Lipoaspirate (ml) Blood (ml) Platelet-rich
plasma (ml)
Healthy subjects
#2 Male Medial knee 85 110 20 10
#11 Male Abdomen 43 120 20 12
#12 Female Medial knee 50 92 25 9
#14 Female Abdomen 54 93 20 10
#19 Female Abdomen 44 120 25 10
Sclerodermic patients
#1 Female Medial knee 6 110 25 12
#2 Female Medial knee 16 140 25 12
#3 Female Medial knee 8 92 25 12
#4 Male Abdomen 3 93 20 9
#5 Male Abdomen 3 120 25 9
#6 Female Medial knee 20 90 25 13
aAge of healthy subjects; disease duration for sclerodermic patients
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Tissue morphological analysis
Undigested lipoaspirates collected from SSc patients and
healthy subjects were included in paraffin-embedded
sections and then stained for hematoxylin and eosin
(H&E) according to standard protocols.
Osteogenic, chondrogenic, and adipogenenic differentiation
SSc and healthy AD-MSCs were plated into 24-well cell
culture plates (50 × 103 cells/well). Cells were allowed to
adhere and cultured in the presence of STEMPRO®
Osteogenesis, Chondrogenesis, or Adipogenesis Differ-
entiation media (Invitrogen) for up to 28 days. Cell
viability, adhesion, and differentiation capacity were de-
termined by daily observation using optical microscopy.
After 28 days the samples were fixed in 2% PFA for
30 min at 37 °C and washed in PBS. The osteogenic dif-
ferentiation was assessed by performing von Kossa stain-
ing for calcium deposition (Polysciences). Chondrogenic
differentiation was assessed through alcian blue staining.
Chondrocytes and osteoblasts were then counterstained
with nuclear fast red (Polyscience). The adipogenic
phenotype was assessed via AdipoRed assay (Lonza) for
10 min at RT, nuclei were counterstained with DAPI
(Thermofisher), and the staining was observed using a
fluorescence microscope (Olympus BX 60).
Gene expression
Total RNA of SSc and healthy AD-MSCs was extracted
using the RNeasy Mini Kit (Qiagen) and 0.8 μg of each
sample was retro-transcribed into cDNA using the RT2
First strand kit (Qiagen) as recommended by the manu-
facturer. Expression analysis of MSC genes was performed
through RT2 profiler PCR array (Qiagen PAHS-082Z) ac-
cording to the manufacturer’s instructions. Data analysis
was performed by RT2 Profiler PCR Array Data Analysis
version 3.5 (Qiagen).
Activated PRP preparation
Venous blood samples (25 cm3) were collected from
healthy and SSc donors. PRP samples were isolated
using Arthrex ACP syringes. These syringes were previ-
ously filled with 1.5 cm3 of 3.8% sodium citrate to pre-
vent clotting of sample. Blood samples were processed
with Rotofix 32-A (Hettich) according to the manufac-
turer’s instructions. Approximately 10–12 cm3 of PRP
was obtained.
SVF and PRP cytokine analysis
SVFs were collected from the upper phase of lipoaspi-
rates following digestion. PRPs were harvested from
blood samples. PRP and SVF samples were filtered using
0.45-μm filters (Corning) and then stored at –80 °C until
use. After thawing, all the samples were analyzed in a
single run in which cytokine quantification was assessed
using the Bio-Plex Pro™ Human Cytokine 21-plex and
27-plex Assay (Bio-Rad). Raw data were analyzed by
Bio-Plex Software (Bio-Rad).
Surgical techniques
The PRP was injected in perioral and malar areas, di-
vided proportionally between the right and left sections
of the face. After 10 min, in the same PRP injection spot,
the lipo-transfer was performed with a 15-gauge infiltra-
tion cannula.
The injection was performed slowly to limit mechan-
ical damage, and then 500 mg of Solu-Medrol was
administered to minimize tissue inflammation and post-
operative edema. Compressive medication was applied
to the area of injection. Patients remained under obser-
vation for 24 hours. In both the abdomen and medial
knee sampling sites, a stitch was applied with Ethilon 4-
0 thread. The medial knee point was covered by elasto-
compressive stockings for about 4 weeks to reduce
edema and facilitate tissue stranding, while the abdomen
was protected by an abdominal sheath.
Instrumental analysis
Patients were evaluated preoperatively and postopera-
tively for a period of 3 months. Morpho-dynamic ana-
lysis was performed through the acquisition of digital
images and with electronic caliber (Profi Line), checking
the degree of opening and extension of the labial rhyme.
Skin stretching capacity was measured using the
Elastometer-EM 25 (G.F. Secchi), and was calculated
using the formula:
Elasticity ¼ b−að Þ=að Þ  100;
where a is the maximum depth of penetration of the skin
and b is the relaxation of the skin. Videodermatoscopic
analysis for cutaneous vascularization was conducted
using a videodermatoscope (Easyscan model; Pico).
Clinical outcome evaluation
The postoperative evaluation consisted of two phases. A
t the initial inspection (first week), the face bandages
were removed, the stitches were checked and then re-
moved from the sampling areas, the site was disinfected,
and gauze with gentamicin was applied. The compres-
sion stockings and abdominal sheath were worn for
1 month. During the second check (after 3 months), the
opening and extension indexes of the labial rhyme were
evaluated by caliper. The cutaneous elasticity index of
the upper left lip and of the left upper cheek was evalu-
ated using a skin suction elastometer. To document the
change in vascularization, two snapshots were taken
of the upper left lip through the videodermatoscope
both in artificial and UV light. Patient’s satisfaction
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was rated through a questionnaire composed of 14
points, in which the numerical evaluation scale used
was “1” being the lowest and “10” being the highest
level of satisfaction.
Statistical analysis
Data are expressed as mean ± standard deviation
(SD). Statistical significance was calculated by apply-
ing Student’s t test. Significance levels were indicated
as p values.
Results
SSc adipose tissue is characterized by a different architecture
and cell composition
In order to define whether adipose tissue from SSc pa-
tients differs from that present in the healthy subjects,
we analyzed the tissue at the histopathological level on
paraffin-embedded sections. Of note, we observed a
clear disorganization of cell structure in the adipose tis-
sue of all SSc patient samples analyzed, as compared to
those of healthy donors (Fig. 1a).
While the SVF from SSc patients showed significantly
lower expression levels of the putative MSC marker
CD271 [20] compared to that isolated from healthy sub-
jects, this variation was not evident in the long-term
propagated AD-MSCs, which were grown in vitro as
spheroids (Fig. 1b). These findings suggest that mesen-
chymal stem-like cells expressing CD271 are enriched
during selective culture conditions.
Isolated and in-vitro propagated AD-MSCs from adi-
pose tissue of SSc patients expressed CD44, CD29, CD9,
and CD73 to a lesser extent than those derived from
healthy individuals (Fig. 1c).
These data suggest that SSc patients suffer from a dis-
organized adipose tissue structure, characterized by a
smaller number of cells with a stem-like phenotype. For
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in freshly isolated SVF and long-term propagated AD-MSCs from healthy donors and SSc patients, performed by flow cytometry. Data are
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these reasons, a detailed and thorough analysis of the
multipotential capacity of SSc AD-MSCs is strongly
required.
SSc AD-MSCs are multipotent but unable to generate
mature functional phenotypes
To investigate the multilineage differentiation capabil-
ities of AD-MSCs, we allowed them to differentiate
toward adipocytes, osteocytes, and chondrocytes in the
presence of a specific differentiation tissue culture
medium (Fig. 2a). Following specific differentiation,
although AD-MSCs from SSc patients showed a great
percentage of cell lineage commitment, they displayed
an aberrant multipotent differentiation capacity in
adipocytes and osteocytes when compared with AD-
MSCs from healthy subjects (Fig. 2b). This aberrancy
consisted of an incomplete maturation of the adipo-
progenitor and osteo-progenitor cells as highlighted by
the presence of small lipid droplets (AdipoRed staining)
and the absence of calcium deposits (von Kossa stain-
ing), respectively (Fig. 2b). Alcian blue analysis revealed
that the functional differentiation of chondrocytes was
impaired in the adipose spheroid-derived adherent cells
of SSc patients. This was shown by a significant
reduction in cell commitment coupled with a lack of
chondrocyte agglomeration (Fig. 2c). In accordance with
the functional alterations observed in AD-MSCs from
SSc patients, a downregulation of MSC-related genes
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underlined a blockage in a late stage of commitment,
impeding the completion of the maturation process
(Fig. 2d).
In particular, we found a downregulation of the master
regulator of cell differentiation JAG1, a Notch ligand, as
well as an upregulation of proinflammatory factors such
as CSF2 (GM-CSF) and CSF3 (G-CSF) in the AD-MSCs
of SSc patients. Thus, these data suggest that the inflam-
matory state, which characterizes SSc patients, could
cause an impairment of the physiological differentiation
mechanisms.
SSc samples have a high content of proinflammatory
cytokines and a shortage of angiogenic factors
Having a high regard for the proinflammatory pheno-
type shown by the AD-MSCs purified and propagated
from SSc patients, we sought to investigate the mi-
croenvironmental cytokines produced by platelets (PRP)
and cells within SVF. Importantly, this characterization
was performed prior to treating patients with Solu-
mederol. Higher levels of MIP-1a, TNF-β, b-NGF,
IL-18, and IL-1α proinflammatory cytokines and
lower levels of IL-1ra anti-inflammatory cytokine
were found in the SVF isolated from SSc patients
when compared with the corresponding fraction
from healthy subjects (Fig. 3a). Analysis of cytokines
present in PRPs from four healthy donors and four
SSc patients showed comparable expression levels of
anti-inflammatory cytokines, including IL-13, IL-10,
IL-4, and IL-1ra (Fig. 3b). Although VEGF and HGF
were barely produced by the SVF of SSc patients,
their presence was significantly higher in the related
PRP (Fig. 3c).
These data reveal that cytokines released by cells
present in the SVF of SSc patients are likely to
boost the inflammation process that is responsible
for the failure of autologous SVF injection alone as
regenerative treatment for SSc patients. Consistently,
the autologous administration of SVF in combin-
ation with PRP could lead to the inhibition of the
inflammation favoring the adipose tissue regener-
ation process.
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SSc patients treated with PRP and SVF showed a substantial
increase of morphofunctional parameters and capillary
density in the maxillofacial region
Six SSc patients were enrolled to test the efficacy of the
combinatorial administration of autologous SVF and PRP
in seeking improvement in morphological and functional
aspects of the facial area (Table 1). Notably, perioral and
malar areas coinjected with autologous SVF and PRP led
to a substantial increase in skin elasticity (16.64% for the
lip and the 17.80% for the cheek), resulting in a marked
improvement of the opening and extension benchmarks
of the labial rhyme (Fig. 4a, b left and middle panels, c).
The enhancement of morphological facial parameters
was maintained up to 3 months after the autologous ad-
ministration of SVF in combination with PRP (Fig. 4c).
Longitudinal skin wrinkles of the upper lip were ironed
out and the profile of both lips was more harmonious,
less tense, full, and softer. The evaluation of the labial
rhyme opening rate showed an increase in five of the six
enrolled patients, while six of six showed a labial rhyme
extension increment (Fig. 4c). In accordance with our
ex-vivo findings, the videodermatoscope vascular exam-
ination of SSc patients who had undergone the combina-
torial treatment showed an increase of capillary density
A BPre-operative Post-operative
C
Patients (#)
Capillary density Vasal ectasia
Pre Post Pre Post
#1 Poor Increased Poor Decreased
#2 Normal Stable Normal Stable
#3 Poor Increased Poor Stable
#4 Poor Stable Normal Decreased
#5 Poor Increased Normal Increased
#6 Poor Increased High Decreased
Patients (#)
Lip skin elasticity Cheek skin elasticity
Pre Post Fold change (%) Pre Post Fold change (%)
#1 57.67 69.00 19.65 58.67 70.67 20.45
#2 63.33 78.67 24.21 60.67 71.67 18.13
#3 48.67 56.00 15.06 44.67 54.67 22.39
#4 73.33 85.67 16.81 61.00 68.67 12.57
#5 60.67 66.67 9.89 74.00 83.00 12.16
#6 54.00 61.67 14.19 58.33 70.67 21.14
Patients (#)
Labial rhyme opening Labial rhyme extension
Pre Post Fold change (%) Pre Post Fold change (%)
#1 34.94 32.42 -7.21 55.66 58.12 4.42
#2 31.72 40.35 27.21 60.58 69.47 14.67
#3 14.42 39.93 176.91 59.40 62.75 5.64
#4 22.48 40.10 78.38 50.90 60.24 18.35
#5 27.55 30.45 10.53 38.70 50.60 30.75
#6 32.12 43.12 34.25 51.76 61.01 17.87
Fig. 4 Combinatorial treatment benefits for SSc patients. a SSc patient preoperative controls (upper Patient #3, lower Patient #6). Malar and perioral
area morphological evaluation (left panels). Evaluation of open and extension rates of the labial rhyme performed with an electronic gauge (middle
panels). Left margin lip capillary density and vascular ectasia evaluation (right panels). b SSc patient postoperative controls as reported in a. c
Videodermatoscopic surgery: capillary density values (upper left) and vascular ectasia parameters (upper right). Clinical elastomeric indexes:
perioral area percentage increase (middle left) and malar area increase percentage (middle right). Operative labial rhyme opening and extension rates:
average percentage of the variation openings parameter (down left) and extension parameter (down right)
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(4/6 patients) and a decreased vascular ectasia (2/6 pa-
tients), thus suggesting an induction of the neoangiogen-
esis processes (Fig. 4a, b, right panels). The perception
of patient care was promising for all of the analyzed pa-
rameters (Tables 2 and 3).
These data show that a single shot of coinjected au-
tologous SVF and PRP in the facial area of SSc patients
could be considered a promising regenerative therapy.
Discussion
Despite the high number of MSCs in adipose tissue and
the many documented therapeutic successes in the fields
of tissue engineering, the exclusive use of lipofilling has
shown an inefficient regeneration in SSc patients [35].
Here, we demonstrate that the injection of autologous
adipose tissue-derived SVF, enriched in MSCs, in com-
bination with PRP, into the perioral and malar areas of
SSc patients not only improved the facial morphofunc-
tional issues, but significantly enhanced the buccal’s
rhyme, skin elasticity, and vascularization.
The use of MSCs has been introduced relatively re-
cently in the clinical practice of regenerative medicine.
Several studies highlighted their self-renewal, multiline-
age differentiation capacity, and immunomodulatory
properties [39]. As well as being multipotent stem cells,
the MSCs are able to differentiate into different cell
types including adipocyte, chondrocyte, osteoblast,
and neuron-like cells [39]. Among their properties,
their accessibility and easy expansion suggest that use
of MSCs may be a useful therapeutic approach for
several disorders.
Nowadays adipose tissue is considered an innovative
source of MSCs suitable for cell-based therapy. Autolo-
gous micrografting of AD-MSCs was recently demon-
strated to induce positive effects on SSc patients [40].
Griffin et al. [41] recently established that AD-MSCs
from healthy individuals and SSc subjects present the
same phenotype and differentiation capacity, while mi-
gration and proliferation are impaired.
Notably, significant difference in the SVF composition
characterized the adipose tissue obtained from SSc pa-
tients as compared to that from healthy subjects. The
adipose compartment of SSc patients showed a disrup-
tion of its peculiar morphology and a bare presence of
mesenchymal cells, thus suggesting that the inflamma-
tory microenvironment, typical of this systemic disease,
could affect the architecture and the adipose cell reser-
voir. Indeed, the abnormal presence of proinflammatory
cytokines in the adipose tissue compartment of SSc
patients impaired the differentiation and maturation
of MSCs toward the adipose phenotype. Accordingly,
mesenchymal stem cell-like traits of MSCs purified
from SSc patients significantly differed from those of
healthy subjects.
Although both AD-MSCs derived from healthy and
SSc SVFs contained a subpopulation positive for CD271,
a putative adipose stem cell marker [20], the SSc AD-
MSCs lacked the ability to differentiate into functional
mesenchymal cellular types. Cells within the SVF in SSc
patients, according to their MSC-related gene profile
and proliferation rate, are likely to be in a late stage of
commitment, which impairs the ultimate phase of cell
differentiation. Several transcription factors are known
to play a crucial role in the last steps of differenti-
ation, thus regulating cell maturation of AD-MSCs
in adipocytes, osteocytes, or chondrocytes, such as
CCAAT/enhancer-binding protein alpha (CEBPα)
Table 2 Perception of patient care
Mr/Mrs............................................... Date.............................
Please express yours opinions with a number from 1 to 10, where 1
corresponds to dissatisfied and 10 very satisfied.
1. How much were you satisfied by the aspect of your lips (before
surgery)? _____
2. How much were you satisfied by the skin elasticity of the perioral
area (before the intervention)? _____
3. How much were you satisfied by the aspect of the malar area (before
surgery)? _____
4. How much were you satisfied by the skin elasticity of the malar area
(before surgery)? _____
5. Indicate the discomfort felt during the opening of the labial rima
(before surgery). _____
6. Indicate the discomfort felt during the extension of the labial rima
(before surgery). _____
Rating 3 months. Date………………………..
1. How much are you satisfied by the aspect of your lips (after surgery)?
_____
2. How much are you satisfied by the skin elasticity of the perioral
region (after surgery)? _____
3. How much are you satisfied by the aspect of the malar (after
surgery)? _____
4. How much are you satisfied by the skin elasticity of the malar region
(after surgery)? _____
5. Indicate the discomfort you feel during the opening of the labial
rhyme (after surgery). _____
6. Indicate the discomfort you feel during the extension of the labial
rhyme (after surgery). _____
General evaluation.
7. Will you do again this type of procedure? _____
8. Would you recommend this procedure to other people with the
same disease? _____
Table 3 Survey satisfaction of patients: preoperative and
postoperative satisfaction values
Parameter Preoperative index
mean (1–10)
Postoperative index
mean (1–10)
Appearance of the lips 3 8
Perioral skin elasticity 3.16 8.83
Malar area aspect 3.33 9.33
Malar skin elasticity 3.16 9.5
Labial rhyme opening
discomfort
2.83 7.83
Labial rhyme extension
discomfort
3 8
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[42], runt-related transcription factor 2 (RUNX2) [43], or
SOX-9 [44], respectively. Likewise, the failure of AD-MSCs
from SSc patients in functional differentiation could
also depend on a delayed maturation block due to a
dysregulation at the transcriptional level.
Vascular damage and alteration of subcutaneous
microcirculation caused by angiogenic factor deficiency
are described to be among the major clinical signs of
SSc patients [10, 32]. The SSc SVF compartment
defected in the production of several master regulators
of angiogenesis, which is crucial for both engraftment
and tissue regeneration. Despite the significant advances
in the therapeutic options for the treatment of SSc pa-
tients, the novel pharmacological compounds that target
the hypoxia signaling pathways and immune response
have not yet proven beneficial to quality of life.
Conclusions
Our evidence supports the hypothesis that coinjection of
autologous SVF and PRP in SSc patients could provide
the correct balance of angiogenic and growth factors to
improve tissue regeneration, thus representing an opti-
mal combinatorial therapy against SSc.
Additional files
Additional file 1: Figure S1. showing AD-MSCs from both healthy subjects
and SSc patients with increased levels of CD271 expression. Representative dot
plot showing the expression of CD271 corresponding isotype match control in
freshly isolated SVF and long-term propagated AD-MSCs from healthy subjects
(upper panels) and SSc patients (lower panels), performed by flow cytometry.
(PDF 205 kb)
Additional file 2: Figure S2. showing AD-MSCs from SSc patients with
decreased levels of mesenchymal stem cell markers. Representative dot
plot showing the expression of CD44, CD90, CD271, CD29, CD73, and CD9
in AD-MSCs from healthy subjects (upper panels) and SSc patients (lower
panels). Small boxes show isotype match control staining. (PDF 316 kb)
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